筋消耗性疾患の世界市場レポート 2024

筋消耗性疾患の市場規模は、今後数年間で急速に成長すると予想されています。 2028年には14.8%の年間複合成長率（CAGR）で261億1,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、規制上の支援、患者擁護団体の取り組み、ヘルスケアインフラの継続的な開発、臨床試験の世界化、個別化医療アプローチの採用増加などの要因に起因すると考えられます。この期間に予想される主な動向には、遠隔医療の普及、診断における継続的な技術進歩、製品イノベーションへの注力、コラボレーションとパートナーシップの増加、治療法の進歩、分子メカニズムに関する進行中の調査、生物医薬品のイノベーションの急増などが含まれます。これらの動向は集合的に、指定された予測期間における予測される成長に貢献します。

座ってばかりのライフスタイルへの支持の増加が予想され、将来の筋消耗性疾患市場の成長を促進する態勢が整っています。限られた身体活動と最小限の運動を特徴とする座りっぱなしのライフスタイルは、筋肉機能への悪影響と関連しています。これにより、筋力と持久力が低下し、筋消耗性疾患に影響を与える可能性があります。 2022年、世界保健機関は、青少年の80%以上、成人の27%以上が推奨される身体活動レベルを満たしていないと報告しました。この座りがちなライフスタイルへの傾向は、筋消耗性疾患市場の拡大を推進する重要な要因です。

筋消耗性疾患市場の主要企業は、筋消耗性疾患を持つ患者のニーズに適切に対応するために、革新的な製品、特に新しい遺伝子治療を積極的に開発しています。新しい遺伝子治療には、治療効果を達成するために遺伝子発現を操作したり、生細胞の生物学的特性を変更したりすることが含まれます。たとえば、米国に本拠を置くバイオテクノロジー企業であるサレプタ・セラピューティクスは、2023年6月にエレビディスを導入しました。エレビディスは、4～5歳の小児患者のデュシェンヌ型筋ジストロフィー（DMD）に対して米国FDAによって承認された最初の遺伝子治療であり、組換え遺伝子治療を利用して、ジストロフィンタンパク質の選択されたドメインを持つ短縮タンパク質をもたらす遺伝子を送達します。この治療は、1回の静脈内注入として投与されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の筋消耗性疾患市場、治療タイプ別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 薬剤
• 理学療法
• 栄養療法
• 手術
• 遺伝子治療
• その他の治療タイプ
• 世界の筋消耗性疾患市場、疾患タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 筋ジストロフィー
• 筋萎縮性側索硬化症（ALS）
• その他の疾患タイプ別
• 世界の筋消耗性疾患市場、エンドユーザー別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院
• リハビリセンター
• 専門クリニック
• その他のエンドユーザー

第7章 地域および国の分析

• 世界の筋消耗性疾患市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の筋消耗性疾患市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 筋消耗性疾患市場の競合情勢
• 筋消耗性疾患市場の企業プロファイル
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • Roche Holding AG
  • Novartis AG
  • Sanofi

第31章 その他の主要および革新的な企業

• GlaxoSmithKline（GSK）
• Eli Lilly and Company
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals
• Acceleron Pharma Inc.
• Biogen Inc.
• Santhera Pharmaceuticals Holding AG
• Mitsubishi Tanabe Pharma
• Nippon Shinyaku Co. Ltd.（NS Pharma, Inc.）
• Sarepta Therapeutics Inc.
• PTC Therapeutics Inc.
• Ionis Pharmaceuticals Inc.
• Axogen, Inc.
• FibroGen Inc.
• Cytokinetics Incorporated

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Muscle wasting disorders, also known as muscle atrophy or muscle wasting, encompass a range of conditions marked by the gradual reduction of muscle mass and strength. This phenomenon can be attributed to various factors, such as lack of use, aging, malnutrition, neurodegenerative diseases, and specific medical conditions.

Primary treatments for muscle wasting disorders include medications, physical therapy, nutritional therapy, surgery, gene therapy, and various other interventions. Medications for muscle wasting disorders are specifically designed to address conditions such as sarcopenia, cachexia, and muscular dystrophy. The goal of these medications is to enhance muscle mass and improve overall muscle function. They find application in the treatment of conditions such as muscular dystrophy, amyotrophic lateral sclerosis (ALS), and others, being utilized by hospitals, rehabilitation centers, specialty clinics, and other end-users.

The muscle wasting disorders market research report is one of a series of new reports from The Business Research Company that provides muscle wasting disorders market statistics, including muscle wasting disorders industry global market size, regional shares, competitors with a muscle wasting disorders market share, detailed muscle wasting disorders market segments, market trends and opportunities, and any further data you may need to thrive in the muscle wasting disorders industry. This muscle wasting disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The muscle wasting disorders market size has grown rapidly in recent years. It will grow from $12.91 billion in 2023 to $15.06 billion in 2024 at a compound annual growth rate (CAGR) of 16.6%. The growth observed in the historical period can be attributed to several factors, including the increasing aging population, a rise in the incidence of chronic diseases, advancements in research and development, heightened awareness of early diagnosis, and the emergence of innovative therapeutic approaches. These factors collectively contributed to the overall expansion of the concerned domain during the specified historical timeframe.

The muscle wasting disorders market size is expected to see rapid growth in the next few years. It will grow to $26.11 billion in 2028 at a compound annual growth rate (CAGR) of 14.8%. The anticipated growth in the forecast period can be attributed to factors such as regulatory support, initiatives from patient advocacy groups, ongoing development of healthcare infrastructure, the globalization of clinical trials, and the increasing adoption of personalized medicine approaches. Key trends expected in this period involve the widespread adoption of telemedicine, continuous technological advancements in diagnostics, a focus on product innovation, increased collaborations and partnerships, advancements in therapeutics, ongoing research on molecular mechanisms, and a surge in biopharmaceutical innovation. These trends collectively contribute to the projected growth in the specified forecast period.

The anticipated rise in adherence to a sedentary lifestyle is poised to drive the growth of the muscle wasting disorders market in the future. A sedentary lifestyle, characterized by limited physical activity and minimal exercise, has been linked to negative impacts on muscle function. This can result in a reduction in muscle strength and endurance, contributing to muscle wasting disorders. In 2022, the World Health Organization reported that over 80% of adolescents and 27% of adults did not meet recommended physical activity levels. This trend towards a sedentary lifestyle is a significant factor propelling the expansion of the muscle wasting disorders market.

Key players in the muscle wasting disorders market are actively developing innovative products, particularly novel gene therapies, to better address the needs of patients with muscle wasting disorders. Novel gene therapy involves manipulating gene expression or altering the biological properties of living cells to achieve therapeutic effects. For example, Sarepta Therapeutics, a US-based biotechnology company, introduced Elevidys in June 2023. Elevidys, the first gene therapy approved by the U.S. FDA for Duchenne muscular dystrophy (DMD) in pediatric patients aged 4 to 5, utilizes recombinant gene therapy to deliver a gene leading to a shortened protein with selected domains of the dystrophin protein. The therapy is administered as a single intravenous infusion.

In September 2023, Biogen Inc., a US-based biotechnology company, acquired Reata Pharmaceuticals Inc. for $7.3 billion. This acquisition is expected to enhance Biogen's rare disease portfolio, specifically addressing Friedreich's ataxia - a genetic, progressive, and debilitating neuromuscular disorder affecting the nervous system and muscles. Reata Pharmaceuticals Inc., the acquired US-based pharmaceutical company, focuses on developing therapeutics for neuromuscular disorders and muscle wasting disorders, further solidifying Biogen's position in the market.

Major companies operating in the muscle wasting disorders market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Roche Holding AG, Novartis AG, Sanofi, GlaxoSmithKline (GSK), Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Acceleron Pharma Inc., Biogen Inc., Santhera Pharmaceuticals Holding AG, Mitsubishi Tanabe Pharma, Nippon Shinyaku Co. Ltd. (NS Pharma, Inc.), Sarepta Therapeutics Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Axogen, Inc., FibroGen Inc., Cytokinetics Incorporated, Italfarmaco S.p.A., Scholar Rock, Bellerophon Therapeutics, Akashi Therapeutics, aTyr Pharma, Metabolic Solutions Development Company, Synaptogenix, MyoKardia, Inc., MyoTherix Inc.

North America was the largest region in the muscle wasting disorder market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the muscle wasting disorders market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the muscle wasting disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The muscle wasting disorders market consists of revenues earned by entities by providing services such as diagnostic services, medical services, support services and community services. The market value includes the value of related goods sold by the service provider or included within the service offering. The muscle wasting disorders market also includes sales of anabolic steroids, growth hormone, enobosarm and bimagrumab. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Muscle Wasting Disorders Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on muscle wasting disorders market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for muscle wasting disorders ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The muscle wasting disorders market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Treatment Type: Medications; Physical Therapy; Nutritional Therapy; Surgery; Gene Therapy; Other Treatment Types
• 2) By Disorder Type: Muscular Dystrophy; Amyotrophic Lateral Sclerosis (ALS); Other Disorder Types
• 3) By End-User: Hospitals; Rehab Centers; Specialty Clinics; Other End-Users
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Roche Holding AG; Novartis AG; Sanofi
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Muscle Wasting Disorders Market Characteristics

3. Muscle Wasting Disorders Market Trends And Strategies

4. Muscle Wasting Disorders Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Muscle Wasting Disorders Market Size and Growth

• 5.1. Global Muscle Wasting Disorders Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Muscle Wasting Disorders Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Muscle Wasting Disorders Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Muscle Wasting Disorders Market Segmentation

• 6.1. Global Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Medications
• Physical Therapy
• Nutritional Therapy
• Surgery
• Gene Therapy
• Other Treatment Types
• 6.2. Global Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Muscular Dystrophy
• Amyotrophic Lateral Sclerosis (ALS)
• Other Disorder Types
• 6.3. Global Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Rehab Centers
• Specialty Clinics
• Other End-Users

7. Muscle Wasting Disorders Market Regional And Country Analysis

• 7.1. Global Muscle Wasting Disorders Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Muscle Wasting Disorders Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Muscle Wasting Disorders Market

• 8.1. Asia-Pacific Muscle Wasting Disorders Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Muscle Wasting Disorders Market

• 9.1. China Muscle Wasting Disorders Market Overview
• 9.2. China Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Muscle Wasting Disorders Market

• 10.1. India Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Muscle Wasting Disorders Market

• 11.1. Japan Muscle Wasting Disorders Market Overview
• 11.2. Japan Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Muscle Wasting Disorders Market

• 12.1. Australia Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Muscle Wasting Disorders Market

• 13.1. Indonesia Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Muscle Wasting Disorders Market

• 14.1. South Korea Muscle Wasting Disorders Market Overview
• 14.2. South Korea Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Muscle Wasting Disorders Market

• 15.1. Western Europe Muscle Wasting Disorders Market Overview
• 15.2. Western Europe Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Muscle Wasting Disorders Market

• 16.1. UK Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Muscle Wasting Disorders Market

• 17.1. Germany Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Muscle Wasting Disorders Market

• 18.1. France Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Muscle Wasting Disorders Market

• 19.1. Italy Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Muscle Wasting Disorders Market

• 20.1. Spain Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Muscle Wasting Disorders Market

• 21.1. Eastern Europe Muscle Wasting Disorders Market Overview
• 21.2. Eastern Europe Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Muscle Wasting Disorders Market

• 22.1. Russia Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Muscle Wasting Disorders Market

• 23.1. North America Muscle Wasting Disorders Market Overview
• 23.2. North America Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Muscle Wasting Disorders Market

• 24.1. USA Muscle Wasting Disorders Market Overview
• 24.2. USA Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Muscle Wasting Disorders Market

• 25.1. Canada Muscle Wasting Disorders Market Overview
• 25.2. Canada Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Muscle Wasting Disorders Market

• 26.1. South America Muscle Wasting Disorders Market Overview
• 26.2. South America Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Muscle Wasting Disorders Market

• 27.1. Brazil Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Muscle Wasting Disorders Market

• 28.1. Middle East Muscle Wasting Disorders Market Overview
• 28.2. Middle East Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Muscle Wasting Disorders Market

• 29.1. Africa Muscle Wasting Disorders Market Overview
• 29.2. Africa Muscle Wasting Disorders Market, Segmentation By Treatment Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Muscle Wasting Disorders Market, Segmentation By Disorder Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Muscle Wasting Disorders Market, Segmentation By End-User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Muscle Wasting Disorders Market Competitive Landscape And Company Profiles

• 30.1. Muscle Wasting Disorders Market Competitive Landscape
• 30.2. Muscle Wasting Disorders Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche Ltd.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Roche Holding AG
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Novartis AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Sanofi
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Muscle Wasting Disorders Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline (GSK)
• 31.2. Eli Lilly and Company
• 31.3. Teva Pharmaceutical Industries Ltd.
• 31.4. Regeneron Pharmaceuticals
• 31.5. Acceleron Pharma Inc.
• 31.6. Biogen Inc.
• 31.7. Santhera Pharmaceuticals Holding AG
• 31.8. Mitsubishi Tanabe Pharma
• 31.9. Nippon Shinyaku Co. Ltd. (NS Pharma, Inc.)
• 31.10. Sarepta Therapeutics Inc.
• 31.11. PTC Therapeutics Inc.
• 31.12. Ionis Pharmaceuticals Inc.
• 31.13. Axogen, Inc.
• 31.14. FibroGen Inc.
• 31.15. Cytokinetics Incorporated

32. Global Muscle Wasting Disorders Market Competitive Benchmarking

33. Global Muscle Wasting Disorders Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Muscle Wasting Disorders Market

35. Muscle Wasting Disorders Market Future Outlook and Potential Analysis

• 35.1 Muscle Wasting Disorders Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Muscle Wasting Disorders Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Muscle Wasting Disorders Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer